Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells | Human Gene Therapy

Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells | Human Gene Therapy

Human Gene Therapy

Latest Impact Factor: 4.510

Read and share these top-cited articles for free through October 9, 2020:

Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells Bian Hu, Yan Zou, Linlin Zhang, Jiaxing Tang, Gabriele Niedermann, Elke Firat, Xingxu Huang, and Xuekai Zhu  Read Now

An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4−/− Mice Michelle E. McClements, Alun R. Barnard, Mandeep S. Singh, Peter Charbel Issa, Zhichun Jiang, Roxana A. Radu, and Robert E. MacLaren  Read Now

AAV-Mediated TAZ Gene Replacement Restores Mitochondrial and Cardioskeletal Function in Barth Syndrome Silveli Suzuki-Hatano, Madhurima Saha, Skylar A. Rizzo, Rachael L. Witko, Bennett J. Gosiker, Manashwi Ramanathan, Meghan S. Soustek, Michael D. Jones, Peter B. Kang, Barry J. Byrne, W. Todd Cade, and Christina A. Pacak  Read Now

LncRNA HOXA-AS2 Facilitates Tumorigenesis and Progression of Papillary Thyroid Cancer by Modulating the miR-15a-5p/HOXA3 Axis Liangfeng Jiang, Zhiming Wu, Xingcheng Meng, Xiufeng Chu, Hongjun Huang, and Chaoyang Xu  Read Now